Ann Gils

发表

Transferability of antibody pairs from ELISA to fiber optic surface plasmon resonance for infliximab detection

Jeroen Lammertyn, Thierry Verbiest, Maarten Bloemen, 2015, Photonics West - Biomedical Optics.

Antibody-modified iron oxide nanoparticles for efficient magnetic isolation and flow cytometric determination of L. pneumophila

Maarten Bloemen, Carla Denis, Thierry Verbiest, 2015, Microchimica Acta.

His374 of wheat endoxylanase inhibitor TAXI‐I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases

Kurt Gebruers, Kristof Brijs, Guido Volckaert, 2005, The FEBS journal.

Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays

Els Brouwers, Nick Geukens, Thomas Van Stappen, 2015, Therapeutic drug monitoring.

Development of a Genotype 325–Specific proCPU/TAFI ELISA

Els Brouwers, Ann Gils, A. Gils, 2003, Arteriosclerosis, thrombosis, and vascular biology.

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

Ann Gils, P. Rutgeerts, S. Vermeire, 2012 .

Vasculin, a novel vascular protein differentially expressed in human atherogenesis.

Sylvia Heeneman, Ann Gils, M. Daemen, 2003, Blood.

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Maarten Bloemen, Ward Brullot, Thierry Verbiest, 2012, Journal of Nanoparticle Research.

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

Els Brouwers, Nick Geukens, Ann Gils, 2014, Therapeutic drug monitoring.

Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling.

Harald Schwalbe, Francesco Luigi Gervasio, Frederic Rousseau, 2016, Cancer cell.

Value of drug level testing and antibody assays in optimising biological therapy

Ann Gils, S. Vermeire, A. Gils, 2012, Frontline Gastroenterology.